Remus Pharmaceuticals Limited — Investor Meet, 28-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Remus Pharmaceuticals reported strong H2 FY26 consolidated revenue of INR 453 Cr (30% YoY growth) and FY26 consolidated revenue of INR 854 Cr (38% YoY growth). Standalone PAT for H2 FY26 grew 19% to INR 13 Cr, with 27% margins.

Management highlighted global expansion into over 40 countries, with a strategic focus on increasing B2C contribution from 14% to a targeted 30% for FY27. Key initiatives include in-licensing niche products, strengthening CNS and urology portfolios, and entering the GLP-1/anti-obesity segment. While consolidated margins are influenced by high-volume US distribution, the company remains confident in its asset-light model, regulatory strength, and brand building for sustainable growth.